TABLE III -. Changes in normal P&S measures in RANCHF patients.
| P&S (M ± SD) | RANCHF (n = 11) | NORANCHF (n = 11) | ||||
|---|---|---|---|---|---|---|
| preRAN | 12 months | p | Initial | 12 months | p | |
| 12 mo = 12-month follow-up; 30:15 = (Stand) 30:15 ratio (unitless); E/I ratio (deep breathing) exhalation/inhalation ratio (unitless); LFa = low-frequency area = sympathetic activity (bpm2); M = mean, P&S = parasympathetic and sympathetic measures; NORANCHF = Congestive Heart Failure patients NOt prescribed RANolazine; RANCHF = Congestive Heart Failure patients prescribed RANolazine; RFa = respiratory frequency area = parasympathetic activity (bpm2); SB = sympathovagal balance = LFa/RFa; SD = standard deviation; VR = Valsalva ratio (unitless). | ||||||
| Rest | ||||||
| LFa | 1.32 ± 1.41 | 0.81 ± 0.90 | 0.054 | 0.89 ± 0.73 | 1.09 ± 0.99 | 0.041 |
| RFa | 0.88 ± 0.85 | 1.51 ± 2.10 | 0.078 | 0.63 ± 0.58 | 0.53 ± 0.92 | 0.016 |
| SB | 0.91 ± 0.72 | 0.53 ± 1.34 | 0.017 | 1.51 ± 0.83 | 4.73 ± 4.89 | 0.020 |
| Deep breathing | ||||||
| RFa | 13.6 ± 15.2 | 8.51 ± 12.4 | 0.954 | 2.54 ± 3.44 | 9.06 ± 12.1 | 0.066 |
| E/I ratio | 1.13 ± 0.09 | 1.15 ± 0.23 | 0.672 | 1.11 ± 0.13 | 1.09 ± 0.08 | 0.170 |
| Valsalva | ||||||
| LFa | 37.7 ± 39.1 | 41.3 ± 64.4 | 0.021 | 9.79 ± 15.1 | 12.1 ± 14.1 | 0.096 |
| VR | 1.25 ± 0.18 | 1.19 ± 0.14 | 0.524 | 1.16 ± 0.11 | 1.16 ± 0.12 | 0.141 |
| Head-up postural change (stand) | ||||||
| LFa | 2.49 ± 4.04 | 0.71 ± 0.93 | 0.091 | 1.79 ± 3.50 | 0.87 ± 0.92 | 0.091 |
| RFa | 2.20 ± 3.66 | 0.51 ± 0.91 | 0.590 | 0.97 ± 1.18 | 0.72 ± 0.81 | 0.055 |
| 30:15 | 1.21 ± 0.15 | 1.10 ± 0.09 | 0.704 | 1.15 ± 0.13 | 1.13 ± 0.09 | 0.377 |